Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1985)	4/8/2004 3:40:34 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

Yes Ian, the BLP25 lung cancer vaccine boosted survival "for some patients" (about 3.4 months longer) in a study of 171 participants. But, as I emphasized in my previous comment, the results weren't statistically significant. It reminds me of the results with Theratope vaccine on breast cancer, that on PII showed very encouraging results but on PIII failed to show an statistically significant result, albeit it is still possible that it may turn out to be statistically significant in a subset of patients. In the mean time the stock needs to hold above its support at $1.70 or break resistance above $2 in order to test its March 2 H at 2.45 RAGL Bernard